||Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Z] 537 active entries
Phone: +49 89 8565 2300
Fax: +49 89 8565 2305
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
The basis of Ingenium's business is its knowledge and expertise in generating the biological information critical to the discovery, validation and development of therapeutics. Ingenium's Deductive GenomicsTM technology combines genome-covering mutagenesis in the murine model system with a proprietary, therapeutic goal-oriented biological screen. From the breadth of knowledge generated by Deductive GenomicsTM, Ingenium is currently advancing a pipeline of novel models and biologically validated drug targets in the areas of obesity, mucosal barrier function and pain management. The company's INGENOtyping platform offers the most rapid alternative to producing genetically-altered murine models. Ingenium can provide in less than four months a series of mammalian models that carry unique genetic alterations in any target gene of interest. Ingenium has research partnership agreements with companies such as Elan, F. Hoffmann-La Roche Ltd., Gruenenthal and Bayer Corporation, in addition to numerous international academic collaborations. The Company benefits from funding from premier investors, an experienced management team, and a growing patent portfolio.
Last update of this entry: December 10, 2004